Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for IART
41.49
-0.50 (-1.19%)
Jan 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.38 - 42.35
52 week 27.38 - 45.50
Open 41.78
Vol / Avg. 537,227.00/763,861.00
Mkt cap 3.02B
P/E 53.37
Div/yield     -
EPS 0.78
Shares 74.77M
Beta 0.75
Inst. own 92%
Feb 23, 2017
Q4 2016 Integra LifeSciences Holdings Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 11, 2017
Integra LifeSciences Holdings Corp at JPMorgan Healthcare Conference
Dec 21, 2016
Integra LifeSciences Holdings Corp Extraordinary Shareholders Meeting
Dec 14, 2016
Integra LifeSciences Holdings Corp Regenerative Technology Investor Day - Webcast
Nov 29, 2016
Integra LifeSciences Holdings Corp at Piper Jaffray Healthcare Conference
Oct 27, 2016
Q3 2016 Integra LifeSciences Holdings Corp Earnings Call - Webcast
Oct 27, 2016
Q3 2016 Integra LifeSciences Holdings Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 8.05% 0.78%
Operating margin 12.02% 9.18%
EBITD margin - 21.08%
Return on average assets 4.44% 0.41%
Return on average equity 9.99% 0.94%
Employees 3,500 -
CDP Score - -

Address

311 Enterprise Dr
PLAINSBORO, NJ 08536-3344
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.

Officers and directors

Stuart M. Essig Ph.D. Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter J. Arduini President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Glenn G. Coleman Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
Lisa Evoli Corporate Vice President, Chief Human Resources Officer
Age: 46
Bio & Compensation  - Reuters
Kenneth Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 62
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 60
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 55
Bio & Compensation  - Reuters
Robert T. Davis Jr. Corporate Vice President, President - Orthopedics and Tissue Technologies
Age: 58
Bio & Compensation  - Reuters
Judith E. O'Grady R.N. Corporate Vice President - Global Regulatory Affairs
Age: 65
Bio & Compensation  - Reuters
Daniel L. Reuvers Corporate Vice President, President - Specialty Surgical Solutions
Age: 53
Bio & Compensation  - Reuters